Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Sigma-tau Farmaceutiche Riunite, S.p.a.

Giovanni Salvatori

Maria Ornella Tinti

Claudio Pisano

Paolo Carminati

Luciana Critelli

Rita De Santis

Antonio Inforzato

Mosé Santaniello

Mos&eacute; Santaniello

Romani Luigina

The combination of pentraxin PTX3 with antifungal agents is described for the treatment of fungal infections and particularly for infections caused by. Thanks to the synergistic effect of the two drugs, the combination allows the administration of suboptimal doses of antifungal agent.

Medicament for the treatment of fungal infections particularly aspergillosis

Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for the preparation of a medicament for the treatment of diseases in which the use of the long pentraxin PTX is indicated, particularly infectious and inflammatory diseases and female fertility disorders. These proteins are endowed with therapeutic activity superior to that of glycosylated pentraxin.

Deglycosylated and desialidated long pentraxin PTX3

Esters of L-carnitine and alkanoyl L-carnitines are described which can be used as cationic lipids for the intracellular delivery of pharmacologically active compounds. New esters of L-carnitine and alkanoyl L-carnitines of formula (I) are also disclosed wherein the R groups are as defined in the description.

Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

Esters of I-carnitine or alkanoyl I-carnitines

Growing community of inventors

Rome, Italy

Giovanni Salvatori